Page last updated: 2024-11-13
gw280264x
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
GW280264X: capable of blocking tumor necrosis factor-alpha-converting enzyme (TACE) and the closely related disintegrin-like metalloproteinase 10 (ADAM10) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 91885425 |
SCHEMBL ID | 22889513 |
MeSH ID | M0474450 |
Synonyms (15)
Synonym |
---|
gw280264x |
866924-39-2 |
benzyl((s)-5-((2r,3s)-3-(n-hydroxyformamido)-2-isobutylhexanamido)-6-oxo-6-(thiazol-2-ylamino)hexyl)carbamate |
MS-30361 |
benzyl ((s)-5-((2r,3s)-3-(n-hydroxyformamido)-2-isobutylhexanamido)-6-oxo-6-(thiazol-2-ylamino)hexyl)carbamate , |
benzyl n-[(5s)-5-[[(2r,3s)-3-[formyl(hydroxy)amino]-2-(2-methylpropyl)hexanoyl]amino]-6-oxo-6-(1,3-thiazol-2-ylamino)hexyl]carbamate |
SCHEMBL22889513 |
HY-115670 |
EX-A4730 |
(formylhydroxyamino)-2-(2-methylpropyl)-1-oxohexyl]amino]- 6-oxo-6-(2-thiazolylamino)hexyl]-carbamate |
benzyl n-[(5s)-5-[[(2r,3s)-3- |
CS-0104321 |
AKOS040759593 |
benzyl n-[(5s)-5-[[(2r,3s)-3- (formylhydroxyamino)-2-(2-methylpropyl)-1-oxohexyl]amino]- 6-oxo-6-(2-thiazolylamino)hexyl]-carbamate |
benzyl n-[(5s)-5-[(2r,3s)-3-(n-hydroxyformamido)-2-(2-methylpropyl)hexanamido]-5-[(1,3-thiazol-2-yl)carbamoyl]pentyl]carbamate |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (50.00) | 29.6817 |
2010's | 4 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 23.85
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.85) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |